ムラヤマ ノリオ    Murayama Norio
   村山 憲男
   所属
人間社会学部 心理学科
 
生活機構研究科 心理学専攻
 
生活心理研究所 所属教員
 
生活機構研究科 生活機構学専攻
   職種
准教授
言語種別 英語
発行・発表の年月 2009/06
形態種別 学術雑誌
査読 査読あり
標題 Clinical effects of high oral dose of donepezil for patients with Alzheimer's disease in Japan
執筆形態 共著
掲載誌名 Psychogeriatrics
掲載区分国外
巻・号・頁 9,pp.50-55
著者・共著者 Motohiro NOZAWA, Yousuke ICHIMIYA, Eiko NOZAWA, Yushi UTUMI, Hideki SUGIYAMA, Norio MURAYAMA, Eizo ISEKI, Heii ARAI
概要 Background: Donepezil 10 mg/day gained approval in Japan in August 2007 for the treatment of cognitive dysfunction in advanced Alzheimer's disease.
Methods: We evaluated the efficacy and adverse effects of donepezil when the dose was increased to 10 mg/day in 61 Japanese patients with Alzheimer's disease. Cognitive function was evaluated using the Revised Hasegawa Dementia Scale and mini-mental state examination at the day before starting, and at 4, 8 and 24 weeks after starting donepezil 10 mg/day. The relationship with apolipoprotein E4 was also investigated.
Results: The Revised Hasegawa Dementia Scale and mini-mental state examination scores were not statistically significantly different at any time after starting donepezil 10 mg/day. It can be anticipated that donepezil 10 mg/day will especially inhibit deterioration of cognitive function in advanced Alzheimer's disease. The incidence of adverse events was 11.5%, lower than the rate of 40% or higher recorded during previous clinical trials.
Conclusions: The progression of cognitive dysfunction could be inhibited by increasing the dose of donepezil to 10 mg/day. It was suggested that longer-term treatment with 5 mg/day might lead to fewer adverse events when the dose is increased to 10 mg/day.